SBCM
LXRX icon

Silver Bridge Capital Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Silver Bridge Capital Management’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-1,429
Closed -$22K – 117
2013
Q2 		$22K Buy
+1,429
New +$21.7K ﹤0.01% 243

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Silver Bridge Capital Management's LXRX Position: Q3 2013 in Review

Silver Bridge Capital Management sold out of Lexicon Pharmaceuticals (LXRX) in Q3 2013, closing a stake of 1,429 shares — an estimated $22K sold.

Silver Bridge Capital Management first reported a position in LXRX in Q2 2013 and held it in 1 quarter. The position peaked at $22K in Q2 2013. 102 funds tracked by Wall St. Rank hold LXRX as of Q3 2013.

  • Silver Bridge Capital Management reported no remaining Lexicon Pharmaceuticals position as of Q3 2013 after selling out during the quarter.
  • Silver Bridge Capital Management sold 1,429 Lexicon Pharmaceuticals shares in Q3 2013, an estimated $22K.
  • Silver Bridge Capital Management first reported a position in Lexicon Pharmaceuticals in Q2 2013 and held it in 1 quarter.
  • Silver Bridge Capital Management's Lexicon Pharmaceuticals position peaked at $22K in Q2 2013.
  • 102 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q3 2013.

Based on Silver Bridge Capital Management's 13F filing for Q3 2013.